XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

May 23, 2025

Primary Completion Date

April 30, 2028

Study Completion Date

July 30, 2028

Conditions

Colorectal CancerMetastatic Colorectal Cancer With RAS Mutation

Interventions

BIOLOGICAL

Drug: XS-03, Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

XS-03 orally Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

BIOLOGICAL

Drug: XS-03

XS-03 orally

BIOLOGICAL

Biological: Bevacizumab, Drug: FOLFOX, Drug: FOLFIRI

Bevacizumab intravenously FOLFOX intravenously FOLFIRI intravenously

Trial Locations (1)

Beijing Cancer Hospital, Beijing